Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation (Publication with Expression of Concern. See vol. 50, 2019) (Publication with Expression of Concern. See vol. 50, 2019) (Retracted article. See vol. 50, 2019)
Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation (Publication with Expression of Concern. See vol. 50, 2019) (Publication with Expression of Concern. See vol. 50, 2019) (Retracted article. See vol. 50, 2019)
复制标题
DOI：
10.1161/01.str.28.12.2390
复制
发表时间：
1997-12-01
期刊：
影响因子：
8.3
通讯作者：
Oizumi, K
中科院分区：
文献类型：
--
作者：
Sato, Y;Honda, Y;Oizumi, K
背景和目的维生素K是合成血浆凝血蛋白和骨Gla蛋白及其他骨基质蛋白位点特异性羧化的必需因子。低维生素它已与降低骨矿物质密度。抑制维生素K依赖性凝血的Warfarin疗法已被证明可降低非风湿性房颤患者的卒中风险。我们评估了维生素II和骨矿物质密度在非风湿性房颤患者谁有长期华法林治疗缺血性stroke.Methods血清中收集了61例非风湿性房颤和缺血性中风谁曾与华法林治疗，63中风患者没有华法林，和39名对照组。两组脑卒中患者均出现偏瘫。测定血清中维生素K-1和K-2骨Gla蛋白和25-羟基维生素D。结果治疗组血清维生素K-1浓度（ng/mL）（0.234 +/-0.177 ng/mL）低于未治疗组（0.329 +/-0.284）或对照组（0.553 +/-0.164）。骨Gla蛋白在治疗患者的血清中（1.241 +/- .799 ng/ml）低于未治疗患者（4.476 +/- 3.226）。25-羟基维生素D的浓度在两个患者组中均较低。治疗组患者两侧的骨密度均低于未治疗组（P <0.0001）。维生素K-1和骨Gla蛋白显着相关的骨密度双侧治疗，但不untreatedpatients.Conclusions骨密度显着降低，脑卒中患者与长期华法林治疗比未治疗的患者，无论是华法林诱导的维生素K功能的降低和降低维生素K-1浓度是可能的原因，这种骨质疏松症。
Background and Purpose Vitamin K is an essential factor for synthesis of plasma clotting proteins and for site-specific carboxylation of bone Gla protein and other bone matrix proteins. Low vitamin It has been associated with reduced bone mineral density. Warfarin therapy, which inhibits vitamin K-dependent blood-clotting, has been demonstrated to reduce the risk of stroke in nonrheumatic atrial fibrillation. We evaluated vitamin ii and bone mineral density in nonrheumatic atrial fibrillation patients who had long-term warfarin therapy after an ischemic stroke.Methods Sera were collected from 61 patients with nonrheumatic atrial fibrillation and ischemic stroke who had been treated with warfarin, 63 stroke patients without warfarin, and 39 control subjects. All stroke patients in both groups had hemiplegia. Sera were assayed for vitamins K-1 and K-2 bone Gla protein, and 25-hydroxyvitamin D. Bone mineral density was determined in both second metacarpals.Results Serum vitamin K-1 concentrations (ng/mL) were lower in treated patients (.234 +/- .177 ng/mL) than in untreated patients (.329 +/- .284) or controls (.553 +/- .164). Bone Gla protein was lower in treated patients' sera (1.241 +/- .799 ng/ml) than in untreated patients (4.476 +/- 3.226), Concentrations of 25-hydroxyvitamin D were lower in both patient groups. Bone mineral density was lower on both sides in treated patients than in untreated patients (P < .0001). Vitamin K-1, and bone Gla protein were significantly related to bone mineral density bilaterally in treated but not in untreated patients.Conclusions Bone mineral density was significantly lower in stroke patients with long-term warfarin treatment than in untreated patients, Both warfarin-induced reduction in vitamin K function and lowered vitamin K-1 concentration are probable causes of this osteopenia.